Autologous hematopoietic stem cell transplantation in the treatment of patients with poor-prognosis non-Hodgkin iymphoma
10.3760/cma.j.issn.1009-9921.2009.10.009
- VernacularTitle:自体造血干细胞移植治疗预后不良非霍奇金淋巴瘤的临床分析
- Author:
Bo CHEN
;
Zhiguo WANG
;
Liang XIAO
;
Hao ZHANG
;
Yanling FAN
;
Guoqiong XIA
;
Lin QIU
;
Zhaomin ZHAN
;
Bolong ZHANG
;
Jun MA
- Publication Type:Journal Article
- Keywords:
Lymphoma,non-Hodgkin;
Peripheral blood stem cell transplantation;
Transplantation,autologous;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2009;18(10):606-608
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the therapeutic effectiveness and safety of autologous peripheral blood stem cell transplantation (APBSCT) for poor-risk non-Hodgkin lymphoma (NHL). Methods Ten patients with poor-prognosis NHL were enrolled from October 2003 to October 2008 in our institute. Ten patients were treated by APBSCT with CY+TBI conditioning regimen (Two patients of them were treated by Double-APBSCT with MEC conditioning regimen). Results Hematopoietic reconstitution was observed in all patients.The time of neutrophil count ≥0.5×109L and platelet≥20×109/L were at day 10 (range: 7-14) and day 16 (range: 10-37), respectively. All patients achieved complete remission (CR) after transplantation. Severe toxicity and transplant related mortality were not observed. After a median follow-up of 24 (10-84) months,seven cases were in event-free survival and three cases relapsed. One of three relapsed patients died from progression of disease, the other was still alive after treatment. Conclusion APBSCT in the treatment of patients with poor-prognosis NHL is a safe, convenient and efficient treatment.
